These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 39257123)

  • 1. Heparin-Calibrated Anti-Factor Xa Assay for the Measurement of Direct Anticoagulants such as Apixaban, Rivaroxaban, and Edoxaban.
    Ahn HS; Chae H; Kim Y; Lee HK; Kim H
    Clin Lab; 2024 Sep; 70(9):. PubMed ID: 39257123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations.
    Margetić S; Ćelap I; Delić Brkljačić D; Pavlović N; Šupraha Goreta S; Kobasić I; Lovrenčić-Huzjan A; Bašić Kes V
    Biochem Med (Zagreb); 2020 Feb; 30(1):010702. PubMed ID: 31839722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using a low-molecular weight heparin-calibrated anti-factor Xa assay to assess the concentration of apixaban and rivaroxaban.
    von Horn H; Rasmusson A; Söderblom L; Malmström RE; Antovic J
    Int J Lab Hematol; 2022 Feb; 44(1):163-167. PubMed ID: 34523813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective cohort study on the use of low molecular weight heparin calibrated anti-Xa assay for measurement of direct oral Xa inhibitors in ex vivo patient samples.
    Lim MS; Hayes R; Sharma A; Kitiponchai T; Mohamed M; Mcrae S
    Pathology; 2022 Aug; 54(5):599-605. PubMed ID: 35414442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct oral anticoagulants and heparins: laboratory values and pitfalls in 'bridging therapy'.
    Eller T; Flieder T; Fox V; Gripp T; Dittrich M; Kuhn J; Alban S; Knabbe C; Birschmann I
    Eur J Cardiothorac Surg; 2017 Apr; 51(4):624-632. PubMed ID: 28043992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays.
    Gosselin R; Grant RP; Adcock DM
    Int J Lab Hematol; 2016 Oct; 38(5):505-13. PubMed ID: 27265752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can an anti-Xa assay for unfractionated heparin be used to assess the presence of rivaroxaban in critical situations?
    Shin H; Koh EH; Lee GW; Song HN; Kim HY; Park S
    J Vasc Surg Venous Lymphat Disord; 2020 Sep; 8(5):741-747. PubMed ID: 32113855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-Xa Oral Anticoagulant Plasma Concentration Assay in Real Life: Rivaroxaban and Apixaban Quantification in Emergency With LMWH Calibrator.
    Billoir P; Barbay V; Joly LM; Fresel M; Chrétien MH; Le Cam Duchez V
    Ann Pharmacother; 2019 Apr; 53(4):341-347. PubMed ID: 30378443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of Direct Oral Anticoagulants on Anti-Factor Xa Measurements Utilized for Monitoring Heparin.
    Macedo KA; Tatarian P; Eugenio KR
    Ann Pharmacother; 2018 Feb; 52(2):154-159. PubMed ID: 28862013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Use of heparin calibrated anti-Xa assay for apixaban and rivaroxaban measurement in the context of regional telestroke activity].
    Delassasseigne C; Leroux C; Renou P; Girard D; Lafargue A; Morel S; Belotti PT; Weinmann L
    Ann Biol Clin (Paris); 2023 Jul; 81(3):269-279. PubMed ID: 37329142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a Rapid Qualitative Screen for Anticoagulant Presence.
    Wong S; Slingerland J; Dickerson JA; Pak J; Roach GD; Saifee NH
    J Appl Lab Med; 2024 Mar; 9(2):305-315. PubMed ID: 38101950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limitations of Specific Coagulation Tests for Direct Oral Anticoagulants: A Critical Analysis.
    Ebner M; Birschmann I; Peter A; Härtig F; Spencer C; Kuhn J; Rupp A; Blumenstock G; Zuern CS; Ziemann U; Poli S
    J Am Heart Assoc; 2018 Oct; 7(19):e009807. PubMed ID: 30371316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of a Heparin-Calibrated Antifactor Xa Assay for Measuring the Anticoagulant Effect of Oral Direct Xa Inhibitors.
    Beyer J; Trujillo T; Fisher S; Ko A; Lind SE; Kiser TH
    Clin Appl Thromb Hemost; 2016 Jul; 22(5):423-8. PubMed ID: 26842561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practical Nomogram Predicting Apixaban or Rivaroxaban Concentrations from Low-Molecular-Weight Heparin Anti-Xa Values: Special Interest in Acute Ischemic Stroke Patients.
    Brakta C; Stépanian A; Reiner P; Delrue M; Mazighi M; Curis E; Siguret V
    J Stroke; 2023 Jan; 25(1):126-131. PubMed ID: 36592965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Relationship between the Initial Anti-factor Xa Measurement and the Duration of Direct Oral Anticoagulant Influence in Patients Transitioning to Heparin.
    Plum MD; Hedrick JN; Hockman R; Bazydlo L; Palkimas S
    Pharmacotherapy; 2020 Sep; 40(9):880-888. PubMed ID: 32677060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Commercial Low Molecular Weight Heparin and Homemade Anti-Xa Calibrators to a Commercial Specific Anti-Xa Calibrator for Plasma Rivaroxaban Quantification by Anti-Xa Oral Anticoagulant Plasma Concentration Chromogenic Assay.
    Divsalar B; Kalantari T; Mohebbi S; Bahmanimehr A; Shahsavani A; Borhani-Haghighi A
    Lab Med; 2023 Jul; 54(4):400-405. PubMed ID: 36573788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A universal anti-Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation.
    Willekens G; Studt JD; Mendez A; Alberio L; Fontana P; Wuillemin WA; Schmidt A; Graf L; Gerber B; Bovet C; Sauter TC; Nagler M
    Br J Haematol; 2021 Jun; 193(6):1203-1212. PubMed ID: 33954979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Anti-factor Xa Activity Among Three Different Factor Xa Inhibitors in Non-valvular Atrial Fibrillation Patients with Renal Impairment.
    Tobe A; Osanai H; Tanaka A; Sakaguchi T; Kambara T; Nakashima Y; Asano H; Ishii H; Ajioka M; Murohara T
    Clin Drug Investig; 2020 Jun; 40(6):567-573. PubMed ID: 32314297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of DOAC Stop on coagulation assays in samples from patients on rivaroxaban or apixaban.
    Platton S; Hunt C
    Int J Lab Hematol; 2019 Apr; 41(2):227-233. PubMed ID: 30468572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of direct oral anticoagulants on thrombin generation on Ceveron TGA.
    Pfrepper C; Behrendt LC; Bönigk H; Siegemund T; Metze M; Franke D; Petros S; Siegemund A
    Int J Lab Hematol; 2022 Feb; 44(1):193-201. PubMed ID: 34585540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.